British journal of haematology · 2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akhtar Othman Salim, Szabo Aniko, Bhatlapenumarthi Vineel, Forsberg Mark, Balev Metodi, Patwari Anannya, Cheruvalath Heloise, Bhutani Divaya, Thanendrarajan Sharmilan, Dhakal Binod, Zangari Maurizio, Patel Tanvi, Shrestha Asis, Al-Hadidi Samer, Cooper Dennis, Lentzsch Suzanne, van Rhee Frits, Shah Mansi R, Bag Aishee, D'Souza Anita, Schinke Carolina, Chakraborty Rajshekhar, Shah Nishi, Mohan Meera
Аннотация
The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular immunotherapy. However, their association with outcomes in patients receiving T-cell redirecting bispecific antibodies (bsAb) is unclear. This multi-centre retrospective study examines the association of baseline GPS and CAR-HT scores with outcomes in 126 MM patients treated with bsAb. Overall, 19% were identified as GPS high risk but did not experience increased toxicity or mortality. Conversely, high-risk CAR-HT patients had a higher incidence of infections and inferior survival, suggesting a need for aggressive infection mitigation strategies.